ESPN 51th Annual Meeting

ESPN 2018


 
Impact Of Recombinant Human Erythropoietin Treatment On Left Ventricular mass and cardiac function in Patients With End Stage Renal Disease On Haemodialysis
MONA ZAHRANE 1 NAGLA ABDEL RAHMAN 1 SOHA EMAM 1

1- PEDIATRIC DEPARTMENT-FACULTY OF MEDICINE CAIRO UNIVERSITY
 
Introduction:

long standing anemia in  CRF patients on HD  is associated with LVH ,cardiomegaly and impaired myocardial function SO The aim of this work was to demonstrate the effect of rHu EPO therapy on LVH and LV systolic function in patients with end stage kidney disease.

Material and methods:

Thirty two patients were enrolled in this study, 14 females and 18 males. Their age ranged from 5 to 17 years with 15 age and sex matched  as controls. The inclusion criteria were; the presence of renal anemia , adequate serum iron status with serum ferritin level of 100 ng/ml or more and a transferrin saturation of >20%, normotension or controlled hypertension and no history of heart disease or other systemic illness. We analyzed the laboratory and echocardiographic data before starting EPO treatment and after treatment in period of follow up ranged between 4 and 9 months with a mean of 5.8+/-1.5 months.

Results:

Hb level increased from 8.5+/-1.87 to 9.3+/-1.7 gm/dl, Hct level increased from 25.78+/-6.59% to 28.88+/-5.5%, LVMI showd reduction from 108.8+/-41.97 to 97.13+/-43.9 g/m2 , SV decreased from 59.58+/-21.17 to 53.9+/-18.49 ml and finally CO decreased from 5.74+/-2.2 to 5+/-1.5 L/minute. No significant change was detected regarding the HR, EDV, &ESV. LV systolic function was normal at the start of the work and remained so in the follow up.

Conclusions:

We concluded that in patients with ESRD on chronic hemodialysis, LVH regression can be obtained after partial correction of anemia with rHu EPO which can be also associated with reduction of the high CO  in these cases. Weather this regression would improve outcome in haemodialysis patients remain to be established.